It aims to fight against any new variants, and it uses an innovative method of directly attacking the viral genome: “The efficacy of treating Covid-19 in animal models is almost identical.”
Treating coronavirus infections by preventing virus replication: This is the goal of an international research team led by scientists from the Menzies Institute for Health Research (MHIQ), Griffith University, Queensland, Australia, which has developed a direct application New experimental treatment for hepatitis. Coronavirus disease 2019.
New antiviral treatment
Anti-viral method utilizes Small interfering RNA (siRNA), This is a type of double-stranded ribonucleic acid molecule, the researchers aim to target the highly conserved region of the Sars-Cov-2 virus. In animal models, this treatment has shown an effective effect of 99.9% in reducing viral load. It directly attacks the viral genome and prevents replication.Have potential advantages, not only can deal with Any new variants of Sars-Cov-2 It can also target related coronaviruses such as Sars and Mers. If this development translates into a treatment for humans, then we will provide treatment options for all β-coronaviruses that may emerge in the future.
In addition to identifying siRNA that can effectively inhibit viral replication, the research team has also developed a new system for transporting siRNA into the blood. “We have developed and selected two new formulas at the same time Lipid nanoparticles When these siRNAs are released in the lungs, organs that have been severely damaged during Sars-Cov-2 infectionExplain to researchers in a new study published in the journal Molecular therapy They provided them with details of their work.
The therapy thus developed was tested in mice infected with Sars-Cov-2 and the results showed that “Strongly suppress the virus In the lungsAnd it has a significant advantage in survival without obvious side effects. “Nanoparticles can reach a wide range of lung cells and silence viral genes Said Nigel McMillan of the Covid-19 Antiviral Research Group at Griffith University and the corresponding co-author of the study. Unexpectedly, no traces of the virus were detected in the lungs of the treated mice“.
Prospects for Covid-19 treatment
Overall, the results show how to develop nanoparticle formulations containing siRNA as a therapy for Covid-19 patients, and how to use them for future coronavirus infections by directly targeting the viral genome. “We also show that these nanoparticles are stable for 12 months at 4°C, and More than a month at room temperature -Added the co-author of the study, Kevin Morris (Kevin Morris) from the City of Hope, which is the American Cancer Research and Treatment Center, which has collaborated to develop new antiviral therapies. This means they can also be used in environments with few resources to treat infected patients“.
The research is part of ten projects funded by the Australian government, and part of the most promising development of the plan will receive funding for a phase 1 clinical trial. “If you choose this method, then of course we will be very interestedMcMillan concluded. However, it may take months or even years to get treatment. “Even if Sars-Cov-2 disappears, the coronavirus will not disappear. They have existed for 3000 yearsAnd therapies for related viruses (including viruses that have not yet infected humans) may be very useful in the future.“.